People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Semaglutide is important to Novo Nordisk, as its daily GLP-1 drug Victoza is under pressure from Eli Lilly’s rival Trulicity. Victoza had been market leader with global sales approaching $3 ...

Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous, mislabeled, or impurity-laden knockoff semaglutide drugs. Feel unsure about the market’s next move? Copy trade ...

Novo Nordisk ... for Novo Nordisk and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working ...

Makers of knockoff in-demand weight loss drugs are fast running out of ... pharmacies to continue to produce copycats of Novo Nordisk’s semaglutide while a lawsuit plays out.

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S ’s weight loss drug while ... evidence that demonstrates that the manufactured supply of semaglutide is ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

Novo Nordisk recently decided to seek approval for an oral version of Wegovy, its famous weight loss drug. This oral formulation of semaglutide, the active ingredient in Wegovy, reported positive ...

Novo Nordisk sells semaglutide under the brands Wegovy and Ozempic for weight loss and type 2 diabetes treatment respectively. Image credit: Getty/UCG. A US judge has rejected efforts by a compounded ...

Khalid bin Abdulaziz Al-Falih and several officials, along with representatives from Novo Nordisk and Lifera. Semaglutide GLP-1 treatments are the global market-leading therapeutics for weight ...

The Danish pharma major, the maker of semaglutide blockbusters Ozempic and ... Abbott is the marketing partner for Novo’s insulin. Confirming the development, a Novo Nordisk spokesperson said, “In ...